Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer

Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Oliveira, Rita, Pereira, Filipa Ferreira, Petronilho, Sara, Martins, Ana Teresa, Lameirinhas, Ana, Constâncio, Vera, Caldas-Ribeiro, Inês, Salta, Sofia, Lopes, Paula, Antunes, Luís, Castro, Fernando, de Sousa, Susana Palma, Henrique, Rui, Jerónimo, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761245/
https://www.ncbi.nlm.nih.gov/pubmed/33276477
http://dx.doi.org/10.3390/jcm9123911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761245/
https://www.ncbi.nlm.nih.gov/pubmed/33276477
http://dx.doi.org/10.3390/jcm9123911

Ejemplares similares